eligibility_summary
Inclusion: Adults (>18) with vertebral/basilar dolichoectatic aneurysm not amenable to surgery/endovascular therapy. Exclusion: biologics in past 12 mo, abnormal labs (ANC<1500, Plt<100k, Hgb<8, AST/ALT≥3×ULN, Cr>2.0), untreated/active TB, chronic infections (e.g., HIV, HBV/HCV case-by-case), open leg ulcers, recent serious infection, live vaccine <4 wks, cancer <5 yrs (except some skin/cervix), pregnant/no contraception, recent investigational drug, substance abuse, allergy, psych disorder, noncompliance, unable to undergo MRI.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT02638701 tests infliximab (Remicade), a chimeric IgG1 monoclonal antibody that neutralizes TNF-α, in dolichoectatic vertebrobasilar aneurysms not amenable to surgery. Mechanism: infliximab binds soluble and transmembrane TNF-α, blocking TNFR1/TNFR2 signaling and downstream NF-κB–driven inflammation, lowering cytokines (e.g., IL-1, IL-6), macrophage activation, matrix metalloproteinases, and vascular wall degradation that promote aneurysm growth/rupture. Targets: TNF-α pathway in vascular wall macrophages, endothelial cells, and smooth muscle cells. Phase 1/2, single-arm, dosing 3 mg/kg IV at weeks 0, 3, 7, then every 8 weeks for 12 months, MRI at baseline, 12, and 24 months.